| Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative (NCT00152880) | University Health Network, Toronto | 2005-07-01 |
| Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (NCT00228917) | GlaxoSmithKline | 2005-06-16 |
| A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy (NCT00489151) | Hospital Authority, Hong Kong | 2005-06-01 |
| Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial (NCT00362674) | Bukwang Pharmaceutical | 2005-06-01 |
| Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B (NCT00128544) | Novartis | 2005-05-01 |
| Studies of Immune Responses in Patients With Chronic Hepatitis B (NCT00155155) | National Taiwan University Hospital | 2005-05-01 |
| HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection (NCT00476723) | The HIV Netherlands Australia Thailand Research Collaboration | 2005-04-01 |
| 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection (NCT00114361) | Foundation for Liver Research | 2005-03-01 |
| FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy (NCT00125762) | Afdhal, Nezam, M.D. | 2005-03-01 |
| Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response (NCT00197158) | GlaxoSmithKline | 2005-03-01 |
| Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants (NCT00169442) | GlaxoSmithKline | 2005-02-10 |
| Project UNITY - HIV Risk Reduction and Vaccine Education Interventions (NCT00150098) | New York Blood Center | 2005-02-01 |
| Drug Use Investigation for HEPSERA (Adefovir) Tablet (NCT01863589) | GlaxoSmithKline | 2005-02-01 |
| Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths (NCT00158808) | GlaxoSmithKline | 2005-01-01 |
| A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis (NCT00562783) | Hospital Authority, Hong Kong | 2005-01-01 |
| Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B Cirrhosis (NCT01987791) | Peking University People's Hospital | 2005-01-01 |
| Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People (NCT00100633) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-12-01 |
| Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History (NCT00168194) | The Alfred | 2004-12-01 |
| Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection (NCT00096785) | Bristol-Myers Squibb | 2004-12-01 |
| Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule (NCT00289718) | GlaxoSmithKline | 2004-11-01 |
| Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients (NCT00186836) | St. Joseph's Health Care London | 2004-11-01 |
| Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults (NCT00289770) | GlaxoSmithKline | 2004-11-01 |
| Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination (NCT00219453) | PATH | 2004-10-01 |
| Retrovirus Epidemiology Donor Study-II (REDS-II) (NCT00097006) | National Heart, Lung, and Blood Institute (NHLBI) | 2004-09-01 |
| A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers (NCT00516945) | Hospital Authority, Hong Kong | 2004-09-01 |
| HEPSERA Post Marketing Surveillance (NCT01329419) | GlaxoSmithKline | 2004-08-01 |
| Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose. (NCT00317161) | GlaxoSmithKline | 2004-08-01 |
| Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI (NCT00154531) | National Taiwan University Hospital | 2004-08-01 |
| A Randomized Trial of Vaccine Adherence in Young Injection Drug Users (NCT00244374) | University of California, San Francisco | 2004-08-01 |
| Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma (NCT00155103) | National Taiwan University Hospital | 2004-08-01 |
| Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine (NCT00289796) | GlaxoSmithKline | 2004-07-01 |
| Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317187) | GlaxoSmithKline | 2004-06-08 |
| Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials (NCT00362505) | Bukwang Pharmaceutical | 2004-06-01 |
| A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. (NCT00275652) | Mayo Clinic | 2004-06-01 |
| Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants (NCT00290303) | GlaxoSmithKline | 2004-05-01 |
| Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years (NCT00197119) | GlaxoSmithKline | 2004-05-01 |
| Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs (NCT00343915) | GlaxoSmithKline | 2004-04-21 |
| Hepatitis B Vaccination in HIV-infected Persons (NCT00230061) | Erasmus Medical Center | 2004-04-01 |
| Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule (NCT00289744) | GlaxoSmithKline | 2004-02-16 |
| PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients (NCT00644761) | Gilead Sciences | 2004-02-01 |
| Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths (NCT00107042) | University of North Carolina, Chapel Hill | 2004-02-01 |
| Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth (NCT00106964) | University of North Carolina, Chapel Hill | 2004-01-01 |
| Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (NCT00317135) | GlaxoSmithKline | 2003-12-11 |
| Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (NCT00289731) | GlaxoSmithKline | 2003-11-24 |
| Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers (NCT00240500) | GlaxoSmithKline | 2003-10-01 |
| Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course (NCT01457547) | GlaxoSmithKline | 2003-10-01 |
| LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers (NCT00240526) | GlaxoSmithKline | 2003-10-01 |
| Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg) (NCT00240539) | GlaxoSmithKline | 2003-10-01 |
| Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). (NCT00352963) | GlaxoSmithKline | 2003-09-30 |
| Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine (NCT00197171) | GlaxoSmithKline | 2003-09-01 |
| Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program (NCT00096811) | Bristol-Myers Squibb | 2003-09-01 |
| Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation (NCT00065507) | Bristol-Myers Squibb | 2003-08-01 |
| Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy (NCT00188240) | University Health Network, Toronto | 2003-08-01 |
| A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. (NCT00317174) | GlaxoSmithKline | 2003-07-01 |
| Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201 (NCT00362700) | Bukwang Pharmaceutical | 2003-07-01 |
| Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV (NCT00313274) | Bukwang Pharmaceutical | 2003-07-01 |
| Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group (NCT00313261) | Bukwang Pharmaceutical | 2003-06-01 |
| Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV (NCT00313287) | Bukwang Pharmaceutical | 2003-06-01 |
| Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine (NCT00146835) | GlaxoSmithKline | 2003-04-01 |
| Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT (NCT00230477) | University of Washington | 2003-04-01 |
| Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV. (NCT00158717) | Gilead Sciences | 2003-04-01 |
| Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV (NCT00645294) | Gilead Sciences | 2003-02-01 |
| A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials (NCT01337479) | Bristol-Myers Squibb | 2003-02-01 |
| Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants (NCT00291967) | GlaxoSmithKline | 2002-11-01 |
| Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients (NCT00051038) | Bristol-Myers Squibb | 2002-09-01 |
| A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus. (NCT00044135) | Triangle Pharmaceuticals | 2002-08-01 |
| Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus (NCT00305019) | Bukwang Pharmaceutical | 2002-07-01 |
| Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years (NCT00383591) | GlaxoSmithKline | 2002-03-01 |
| Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) (NCT00092469) | Merck Sharp & Dohme LLC | 2002-03-01 |
| Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis (NCT00160940) | University Health Network, Toronto | 2002-02-01 |
| Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection. (NCT00158704) | Gilead Sciences | 2002-01-01 |
| Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication (NCT00188201) | University Health Network, Toronto | 2002-01-01 |
| A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B (NCT00380614) | Maulana Azad Medical College | 2002-01-01 |
| Prospective Cohort of HIV/HBV-coinfected Patients in Europe (NCT04984772) | Insel Gruppe AG, University Hospital Bern | 2001-10-02 |
| To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines (NCT00366366) | GlaxoSmithKline | 2001-09-01 |
| Lamivudine and Adefovir to Treat Chronic Hepatitis B (NCT00023309) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2001-08-01 |
| Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients (NCT00013702) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-03-01 |
| Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine (NCT00880477) | GlaxoSmithKline | 2001-01-01 |
| Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants (NCT00429481) | GlaxoSmithKline | 2001-01-01 |
| Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants (NCT00879827) | GlaxoSmithKline | 2000-09-01 |
| Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control (NCT00697866) | GlaxoSmithKline | 2000-08-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine (NCT01457560) | GlaxoSmithKline | 2000-02-01 |
| Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age (NCT00697554) | GlaxoSmithKline | 2000-01-01 |
| Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma (NCT02025842) | Azienda Ospedaliera San Camillo Forlanini | 2000-01-01 |
| Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years (NCT00383383) | GlaxoSmithKline | 1999-12-01 |
| Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years (NCT00383227) | GlaxoSmithKline | 1999-12-01 |
| Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y (NCT00698061) | GlaxoSmithKline | 1999-11-01 |
| Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y (NCT00696917) | GlaxoSmithKline | 1999-04-01 |
| Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype (NCT00697749) | GlaxoSmithKline | 1999-04-01 |
| Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately (NCT01457508) | GlaxoSmithKline | 1999-01-01 |
| Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly (NCT01457495) | GlaxoSmithKline | 1998-09-01 |
| Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents (NCT00697775) | GlaxoSmithKline | 1998-03-01 |
| Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan (NCT00001712) | National Institutes of Health Clinical Center (CC) | 1998-02-01 |
| Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y (NCT00698906) | GlaxoSmithKline | 1997-06-01 |
| Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders (NCT00697931) | GlaxoSmithKline | 1997-05-01 |
| Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs). (NCT00697216) | GlaxoSmithKline | 1997-03-01 |
| Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections (NCT00169858) | Laval University | 1995-09-01 |
| Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B (NCT00697840) | GlaxoSmithKline | 1995-06-01 |
| Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B (NCT00698087) | GlaxoSmithKline | 1995-01-01 |
| Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults (NCT00697242) | GlaxoSmithKline | 1994-01-01 |